LAM-001

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Bronchiolitis Obliterans Syndrome · Phase 2

Company guidance: data expected first quarter of 2028 (Quince Therapeutics, 14 Aug 2026). “Society (ATS) in May 2026, the company has advanced LAM-001 into a Phase 2b PH-ILD trial and data is anticipated in the first quarter of 2028.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Bronchiolitis Obliterans Syndrome
Pulmonary Hypertension Associated with Interstitial Lung Disease
Other / comorbidity
NCT07886554 · IRulya Therapeutics Inc.
2026-12 – 2029-06 · Sarcoidosis Associated Pulmonary Hypertension
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
LAM-001: this drugPhase 2Small moleculemTOR (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results).
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
MosliciguatPhase 3Small moleculeSoluble guanylate cyclasenot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Fc-Relaxin Fusion Protein (TX45)Phase 2Protein / enzyme therapeuticRelaxin receptor (RXFP1) / relaxinnot yet gradedNo reviewed efficacy summary in this indication
MirivadelgatPhase 2Small moleculeALDH2not yet gradedNo reviewed efficacy summary in this indication
Onatasertib
Phase 2(overall)
Small moleculemTOR (inhibitor)
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow LAM-001 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Bronchiolitis Obliterans SyndromeRecruiting
Est. primary completion 2026-12 · NCT06018766 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 2Pulmonary Hypertension Associated with Interstitial Lung DiseaseRecruiting
Est. primary completion 2028-03 · NCT05798923 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Sarcoidosis Associated Pulmonary HypertensionNot yet recruiting
Est. primary completion 2028-12 · NCT07886554 · CT.gov ↗
What to watch

See the full readout calendar ↗